Home Tags EpiPen
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
Mylan’s shareholders just voted against its executive pay, which included a $100 million package for its chairman
Mylan shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.
Shareholder advocacy groups are telling Mylan investors to show no mercy with the board at an upcoming shareholder meeting.
Executives at Mylan, the maker of EpiPen, are richly compensated — shareholders think maybe too richly.
The chairman of the company behind the EpiPen reportedly flipped everyone off when they asked about drug pricing
Mylan's chairman reportedly did not mince words when addressing potential drug pricing criticism.
Mylan's chairman Robert Coury made $98 million in 2016, a year in which the company faced criticism for the price of the EpiPen.
The lawsuit accuses Mylan of engaging in a scheme with pharmacy benefit managers to dominate the market.